Skip to main content
. Author manuscript; available in PMC: 2013 May 1.
Published in final edited form as: Mol Cancer Ther. 2012 Aug 14;11(11):2535–2540. doi: 10.1158/1535-7163.MCT-12-0163

Figure 1. Radiographic response to erlotinib in patients with adenosquamous and solid “pseudosquamous” adenocarcinomas harboring EGFR mutations.

Figure 1

† Denotes solid (pseudosquamous) adenocarcinomas; other cases are carcinomas with a squamous component (confirmed or presumed adenosquamous carcinomas).